The role of biomarkers in the diagnostics of chronic inflammatory bowel diseases

Main Article Content

Yu.M. Stepanov
I.V. Psareva


Chronic inflammatory bowel diseases, namely ulcerative colitis and Crohn’s disease, attracted the attention of both doctors and scientists all over the world. There was a trend to an increase in the number of severe, treatment-resistant forms of diseases, complications and surgical interventions that lead to disability in the young, working-age patients. The article shows the problems in the diagnosis of chronic inflammatory bowel diseases (ulcerative colitis, Crohn’s disease).The possibilities of instrumental and laboratory methods of study are shown. Attention is paid to non-invasive diagnostic methods — determination of faecal calprotectin, lactoferrin, lysozyme, elastase, myeloperoxidase, A1-antitrypsin. A literature search was conducted using databases Pub Med, MedLine, EMBASE.

Article Details

How to Cite
Stepanov, Y., & Psareva, I. (2017). The role of biomarkers in the diagnostics of chronic inflammatory bowel diseases. GASTROENTEROLOGY, 51(1), 56–63.
Reviews and Lections


Adler G. Bolezn Krona і yazvennіy kolіt [Crohn’s disease and ulcerative colitis]. Moscow: GEOTAR-MED; 2001. 528 p. (in Russian).

Ivashkin VT, Shifrin OS. Contemporary approaches to the treatment of Crohn’s disease. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2002;2:67-73. (in Russian).

Belousov EA. Yazvennіy kolіt I bolezn Krona [Ulcerative colitis and Crohn’s disease]. Tver: Triada; 2002. 128 p. (in Russian).

Stepanov YuM, Fedorova NS. The real state and prospects in the diagnostics of intestinal diseases. Suchasna gastroenterologyja. 2010;1(51):109-114. (in Ukrainian).

Stepanov YuM, Scherbynina MB, Kononov IN. Suchasni metodi doslidgenya v gastroentorologii: Metod. posib. [Contemporary methods in gastroenterology. Guidelines]. Dnipropetrovs’k; 2006. 155 p. (in Ukrainian).

Stepanov Yu.M., BoykoT.Y. Chvoroba Krona: suchasni pidchodi do diagnostiki ta likuvannya [Crohn’s disease: contemporary approaches to diagnostics and treatment]. Dnipropetrovs’k; 2014. 31 p. (іn Ukrainian).

Mostovoy YuM. Suchasni klasifikacii ta standarti likuvannya rozpovsudgenich zachvoruvan vnutrishnich organiv [Contemporary standards of classification and treatment of internal diseases of internal organs]. Vinnitsa; 2008. 462 p. (іn Ukrainian).

Svintsitskyi AS. Diagnostika ta likuvannya poshirenich zachvoruvan organiv travlennya: Navchalniy posibnik [Diagnosis and treatment of common diseases of the digestive system. Guidelines]. Kyiv: Medknyha; 2007. 296 p. (іn Ukrainian).

Budzak IJ. On the problem of differential diagnosis of inflammatory and functional bowel diseases. Suchasna gastroеnterologyja. 2013;2(48):81-85. (іn Ukrainian).

Marzhatka Z. Terminologiya, opredelenie terminov i diagnosticheskie kriterii v endoskopii pishevaritelnogo trakta [Terminology, definitions and diagnostic criteria in the endoscopy of the digestive tract]. Hamburg (Germany): Normed Verlag; 1996. 123 p.

Nozdrin VI. Express histologiya [Express histology]: Uchebnoe posobie. Manual, 4th edition, enlarged, revised. Moscow: “Honey. Inf. Agency”; 2008. 208 p. (іn Russian).

Sergienko AI. Features of the treatment of ulcerative colitis with liver damage. Ukr. Therapeutic Journal. 2005;1:32-38. (іn Ukrainian).

Sergienko AI. Ranni proyavi I difirenciyna diagnostika chronichnih zapalnih zahvoruvan kishechnika [Early manifestations and differential diagnostics of chronic inflammatory bowel diseases]. Zaporozhye: Wild Field; 2005. 157-163 p. (іn Ukrainian).

Vasilchenko AV. Ways of improving of the efficiency of diagnostics of diseases of the colon during colonoscopy. Abstract; 2002. 19 р.

Grigoriev G. Functional constipation and irritable bowel syndrome: differential diagnosis and treatment. Vrach. 2006;2:3-6. (іn Russian).

Krylova EA. Changes of biochemical parameters in Crohn’s disease and ulcerative colitis. Clean. hir. 2003;11:153-155. (іn Ukrainian).

Golysheva SV, Meshalkina IY, Grigorieva GA. Valuation and forecasting of quality of life in patients with inflammatory bowel disease as a result of long-term monitoring. Gastrojenterologija. 2005;1-2:32-36. (іn Russian).

Grigoriev PY, Ivashkin VT, Komarov FI. Standards (protocols) of diagnostics and treatment of diseases of the digestive system. Praktikujushhij vrach. 1998;2:2-13. (in Rusian).

Zvyagintseva TD, Grydnyeva SV. Contemporary approaches to diagnosis of chronic bowel disease. Ukr. therapeutic journal. 2005;2:44-48. (in Ukrainian).

Komarov FI, Osadchuk AM, Osadchuk MA. Nespecificheskiy yazvenniy kolit [Ulcerative colitis]. M.: Medical News Agency Ltd; 2008. 256 p. (in Russian).

Lazebnik L, Huseynov ZM, Efremov LI. Fecal calprotectin as a biomarker of the effectiveness of various medical vmeschatelstv in patients with inflammatory diseases kishechnika. Eksperimentalnaya i klinicheskaja gastrojenterologija. 2013;8.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer А, Michalsen А, Dobos G. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. J Gastroenterol. 2008;103:162-9. doi: 10.1111/j.1572-0241.2007.01556.x.

Kefalides PT, Hanauer SB. Ulcerative colitis: diagnosis and management. Hospital Physician. 2002;June:53-63.

Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterol. 2006;130:1377-90. doi: 10.1053/j.gastro.2006.03.008.

Nikolaus S, Schreiber S. Diagnostic of inflammatory bowel disease. Gastroenterology. 2007;133(5):1670-89. doi: 10.1053/j.gastro.2007.09.001.

Lee DS. The Role of Endoscopy in Inflammatory Bowel Disease. Medscape Gastroenterology J. 2001;3( 5):34-8.

Roseth AG, Aadland E, Fagerhol MK, et al. Assessment of neutrophil dominating protein calprotectin in feces. J Gastroenterol. 1992;27:793-8.

Scholmerich J. Future developments in diagnosis and treatment of inflammatory bowel disease. Hepatogastroenterology. 2000;47(31):101-14. PMID: 10690590

Best WR, Becktel JM, Singleton JW. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439-44. PMID: 1248701

Bossuyt PM, Reitsma JB, Bruns DE, et al. Toward complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Chem. 2003;49:1-6. doi: 10.1148/radiol.2261021292.

Becker W, Fischbach W, Weppler M, et al. Radiolabelled granulocytes in inflammatory bowel disease: diagnostic possibilities and clinical indications. Nucl Med Commun. 1988;9:693-701. PMID: 3062507

Lorens MH. Inflammatory bowel disease. Lab. Diagnostics. 2001;40.

Saverymuttu SH, Camilleri M, Rees H, et al. Indium 111 Granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal Indium 111Granulocyte Excretion. Gastroenterol. 1986;90:1121-8.

Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51:117-26.

Sherwood RA. Faecal Markers of Gastrointestinal Inflammation. Journal of Clinical Pathology. 2012;65(11):981-5. doi: 10.1136/jclinpath-2012-200901. Epub 2012 Jul 19.

Aqbal D, Abdallah A, Bolloso E, et al. Role of C-reactive Protein in Inflammatory Bowel Disease. Georgetown University. Jouanl of Health Sciences. 2007;4(1):34-6.

Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002;14(4):409-12.

Iskandar HN, Ciorba MA. Biomarkers in Inflammatory Bowel Disease: Current Practices and Recent Advances. Transl Res. 2012;159(4):313-25.  doi: 10.1016/j.trsl.2012.01.001. Epub 2012 Feb 1.

Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005;77:64-77. doi: 10.1086/431366.

Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):661-5.

Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57(11):1518-23. doi: 10.1136/gut.2007.146357. Epub 2008 Jun 19.

Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-protein serum level. Inflamm Bowel Dis. 2007;13:1100-5. doi: 10.1002/ibd.20178.

Angriman I, Scarpa M, D’Incà R, Basso D, Ruffolo C, Polese L, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta 2007;381:63-8. doi: 10.1016/j.cca.2007.02.025.

Dеsаi D, Faubion WA, Sandborn WJ. Biological Activity Markers in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2007;25(3):247-52. doi: 10.1111/j.1365-2036.2006.03184.x.

Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1440-4. doi: 10.1080/00365520701427094.

Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D. et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-14. doi: 10.1111/j.1572-0241.2003.07458.x.

Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-9. doi: 10.1002/ibd.20275.

Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis Colon Rectum. 2007;50:1697-706. doi: 10.1007/s10350-007-0303-9.

Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58(2):176-80. PMID: 9144308

Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with infl ammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-20. doi: 10.1080/00365520410007971.

Konikoff MR, Denson LA. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(6):524-34. PMID: 16775498

Tibbie JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal infl ammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22. PMID: 10889150

Tibble JA, Bjarnason I. Non-invasive investigations of infl ammatory bowel disease. World J Gastroenterol. 2001;7:460-5. doi: 10.3748/wjg.v7.i4.460

Otten CM, Kok L, Witteman BJ et al. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bower syndrome. Clin Chem Lab Med. 2008;46(9):1275-1280. doi: 10.1515/CCLM.2008.246.

Van der Sluys Veer A, et al. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis Sci. 1998;43(3):590-5. PMID: 9539656

Pang T, Leach ST, Katz T, Day AS, Ooi CY. Fecal biomarkers of intestinal health and disease in children. Front Pediatr. 2014 Jan 28;2:6. doi: 10.3389/fped.2014.00006.

Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755-62. doi: 10.1111/j.1572-0241.2002.05837.x.

Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest. 2007;67:810-20. doi: 10.1080/00365510701452838.

Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584-9. PMID: 18810778

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>